Immunoma SARS-CoV-2 antibody cocktail neutralizes UK, South Africa, Brazil and California variants in preclinical testing; Progress to IND repository

  • Neutralizes South Africa (B.1.351) and United Kingdom (B.1.1.7) in live virus testing; Brazil (P.1) and California (B.1.429, also containing B.1.427 mutations) in pseudovirus testing, all of which are designated by the CDC as “Variants of concern”.

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that uses its patient memory B-cell platform to develop therapeutic antibodies, announced the selection of antibodies for its IMM-BCP-01 antibody cocktail and shared data showing that IMM-BCP-01 neutralizes CDC SARS-CoV-2 “Variants of concern” in preclinical tests.

IMM-BCP-01 contains three monoclonal antibodies that bind to non-overlapping regions of the spike protein with picomolar affinity. Antibodies exhibit combinatorial effects in vitro against several variants of SARS-CoV-2, including those with both increased transmission in the United States and resistance to current therapeutic antibodies and vaccines. In summary, Immunoma antibodies have been shown to be effective against the current SARS-CoV-2 and its variants.

Preclinical test results:

  • In Syrian hamsters infected with live SARS-CoV-2 virus (USA-WA1 / 2020), IMM-BCP-01 reduced lung viral load as a treatment and prophylaxis.

  • Studies on live viruses have demonstrated complete neutralization by IMM-BCP-01 of “Variants of Concern”, designated by the CDC, in South Africa (B.1.351) and the United Kingdom (B.1.1.7) , as well as American and European reference strains. WA1 / 2020 and BavPat1 / 2020.

  • Pseudovirus studies have demonstrated complete neutralization by IMM-BCP-01 of “Variants of Concern” designated by the CDC in Brazil (P.1) and California (B.1.429, which also contains B.1.427 mutations. ).

  • Mechanistic studies demonstrate that the selected antibodies not only bind to SARS-CoV-2 peak proteins with complex mutations, especially in UK (B.1.1.7), SA (B.1.351), Brazil (P1 / P2) and California (B. 1.429 / 427), but also to those with several individual mutations, including E484Q and L452R, which are associated with the recently emerged double mutant (B.1.617, or variant India).

  • Two of the three antibodies selected bind to areas of the Spike protein that may be resistant to evolutionary changes.

  • In addition to viral neutralization, antibodies have also demonstrated additional mechanisms in vitro that may be relevant for viral clearance.

“Simply put, the preclinical results we shared today are a testament to our discovery engine’s ability to quickly identify potent and rare antibodies for inclusion in our IMM-BCP-01 antibody cocktail,” Purnanand said. Sarma, Ph.D., President and CEO. of Immunoma. “The strength of our data gives us the confidence to continue advancing IMM-BCP-01 to IND depot. We believe that a combination of antibodies targeting epitopes conserved in known variants is an important aspect, and potentially necessary, from the fight against mutational drift currently seen with SARS-CoV-2. “

“Despite the many challenges created by the COVID-19 pandemic, this has helped strengthen government-industry partnerships to quickly identify solutions,” said Dr Jason Roos, executive director of the Joint Program for Chemical, Biological Defense, radiological and nuclear (JPEO-CBRND). “Demonstrating the ability to collect blood from recovering patients and quickly identify multiple antibodies as preventative or therapeutic agents can not only fight the current pandemic, but can also establish a platform to fight future new viruses.” We are very encouraged by the current results of product development and testing. “

In July 2020, Immunome was awarded a $ 13.3 million agreement from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) of the United States Department of Defense, in collaboration with the Defense Health Agency, to support Immunoma’s COVID program. The research discussed in this press release is part of that program.

Immunome plans to file an IND for its IMM-BCP-001 program at the end of the second trimester and at the start of the third trimester 2021.

About Immunoma

Immunome is a biopharmaceutical company that uses its proprietary human memory B cell platform to discover and develop world-class therapeutic antibodies designed to change the way diseases are treated. The company’s initial goal is to develop therapeutics to treat oncology and infectious diseases, including COVID-19. Immunoma’s proprietary discovery platform identifies novel therapeutic antibodies and their targets by taking advantage of highly qualified components of the immune system, memory B cells, from patients whose bodies have learned to fight their disease. For more information, please visit

Forward-looking statements

This press release includes certain information which contains “forward-looking statements” intended to qualify for the “safe harbor” of liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to limit, express or implied statements regarding Immunoma. beliefs and expectations regarding the advancement of its COVID-19 oncology and therapeutic antibody programs, the execution of its clinical and strategic plans, anticipated future milestones for IMM-BCP-01 and IMM-ONC- 01, including expectations regarding therapeutic potential and its benefits, and IND deposits. Forward-looking statements may be identified by the words “anticipate”, believe ”,“ estimate ”,“ expect ”,“ intend ”,“ plan ”,“ plan ”,“ could ”,“ may ”. , “Could”, “should” “seek”, “potential” and similar expressions. Forward-looking statements are based on Immunoma’s current expectations and are subject to uncertainties, risks and inherent assumptions that are difficult to predict. Factors that may cause actual results to vary include: but not limited to, risks and uncertainties associated with: the impact of the COVID-19 pandemic on business, operations, strategy, goals and milestones planned Immunome; the ability of Immunome to execute its strategy, including with respect to the timing of its R&D efforts, the IND filings, the initiation of clinical studies and other anticipated milestones; the timing and the effectiveness of any anticor-based treatment ps which can be developed by Immunoma; Immunoma’s ability to fund operations; and the additional risks and uncertainties set out further under the heading “Risk Factors” in Immunome’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in Immunoma filings and reports with the SEC. The forward-looking statements contained in this announcement are made as of this date, and Immunome assumes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. , unless this may be required under applicable law.

See the source version on


Contact Immunoma
Corleen Roche
Financial director
Immunoma, Inc.
[email protected]

Investor contact
Laurence Watts
General manager
Gilmartin, LLC
[email protected]

Media contact
Megan McGrath or Nick Chang
[email protected] or [email protected]

Previous CBOT vs CME: what's the difference?
Next Immutep to announce new TACTI-002 and INSIGHT-004 data in poster presentations and discussions at ASCO 2021 annual meeting

No Comment

Leave a reply

Your email address will not be published.